Cadila Healthcare has received final approval to market Pyridostigmine Bromide tablets USP, 60 mg, which is dispensed for the treatment of various neurological disorders.
The estimated sales of the drug in 2015 is $27.9 million as per IMS, the release said.
The group now has 100 proposals and has so far filed over 260 ANDAs since the start of the filing process in FY2003-04, the release added.
